Skip to main content
. 2008 Mar 5;5:39. doi: 10.1186/1743-422X-5-39

Table 2.

Susceptibility of VV Δ F2L-gfp to selected thymidine analogs and cidofovir.

Compound Name VV Δ F2L-gfp (EC50, μM)a VV WR wt (EC50, μM)
IDU 2.5 ± 0.9 2.4 ± 0.6
N-MCT 6.2 ± 3.5 12 ± 1.6
PFT3 2.0 ± 0.6 2.4 ± 0.4
PFT4 2.3 ± 1.1 2.5 ± 0.1
CDV 11 ± 4.2 10 ± 0.3

a. Concentration required to reduce plaque formation by 50%. Values shown are the average of duplicate determinations with the standard deviations shown.